What Changed — And Why It Matters

On 20 March 2026, the core Indian patent for semaglutide — the molecule behind the originator brands used for diabetes and weight management — expired. Within weeks, several Indian pharmaceutical companies received approval to manufacture their own versions, and the cost to patients fell substantially.

Medically reviewed by Dr. Manuj Sondhi, MRCP (UK), MD, DNB — Consultant Physician & Diabetologist, Nirvana Clinic, Greater Noida · Last updated: 10 July 2026
Part of the complete GLP-1 Therapy Guide for India →

The clinical significance is real. Semaglutide was always an effective medicine; for most Indians it was simply unaffordable. With that barrier easing, far more patients can now be considered for evidence-based metabolic treatment — when it is clinically appropriate for them. The right first step, if you are considering it, is a proper medical weight-loss evaluation, not a walk into a pharmacy.

Understanding the Brands: Semaglutide and Tirzepatide

It helps to separate the molecule from the brand name. Two molecules dominate this category:

Semaglutide is the active ingredient originally developed by Novo Nordisk and known by the brand names Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (the oral tablet form). Following the March 2026 patent expiry, the same molecule is now produced by several DCGI-approved Indian manufacturers under a range of brand names. Because the active molecule is identical, the clinical effect of an approved generic is the same as the originator.

Tirzepatide is a different, newer molecule — a dual GIP/GLP-1 agonist — known by the brand name Mounjaro. It does not yet have an Indian generic equivalent, as its patent is still in force.

Which brands exist, and who makes them?

Patients now encounter many unfamiliar brand names at pharmacies and online. The table below is provided purely so you can recognise what you are being offered and verify the manufacturer. It is identification, not comparison or ranking — and deliberately contains no prices.

List not exhaustive — more launches are expected through 2026, and formats and approved indications vary by product and can change. Each brand's approved indication (type-2 diabetes, chronic weight management, or both) is stated on its label; your physician will confirm what applies to you. Always verify the manufacturer, batch number and expiry on any product you are dispensed.

What About the Cost?

The most common question patients ask is about price. Public news reporting has described generic semaglutide as costing dramatically less than the originator brands since the patent expired — widely reported reductions are very large. However, the actual cost varies considerably by molecule, brand, formulation (vial versus pen), dose, city and pharmacy, and it continues to change as more products launch.

For that reason — and because cost should never be the main basis for a medical decision — I do not publish specific drug prices here. The right way to get accurate, current pricing is to ask your treating physician or a licensed pharmacy. In a consultation, the important questions are whether a GLP-1 medicine is appropriate for you at all, which formulation suits you, and how to use it safely — with cost considered as one practical factor among several, not the headline.

Vial vs Pen — What's the Difference?

This is a practical question many patients have. The right choice depends on your comfort with injections, your budget, and whether someone can help you administer it.

Multi-dose vial

Typically the lowest-cost format. A vial contains multiple doses, and each week's dose is drawn using a syringe. It requires more skill: drawing the correct volume, storing the vial properly in the refrigerator, and using a fresh syringe each time. In general this format suits patients who are comfortable with syringes, or who have a family member or caregiver able to administer it correctly.

Pre-filled disposable pen

Click, dial the dose, inject — no measuring or drawing. It is generally more expensive than a vial but considerably easier to use, which often improves adherence.

Reusable multi-dose pen

A reusable pen device in which cartridges are replaced. It can offer good long-term value and precise dose adjustment, and is often a practical option for patients expected to be on therapy for several months.

How a Physician Chooses Between the Options

Patients often ask how a doctor decides between the many available products. Rather than naming brands, it is more useful to understand the factors that actually guide the decision:

Clinical suitability first. Before formulation or brand, the question is whether a GLP-1 medicine is indicated at all — based on your diagnosis, BMI, blood work, other conditions, and contraindications. For many people the appropriate answer is lifestyle-first care, not medication.

Formulation and adherence. The device (vial vs pen) is matched to the individual — their comfort with injections, dexterity, and likelihood of using it consistently. A slightly cheaper option that leads to missed or incorrect doses is a false economy.

Manufacturer reliability. Among approved products, factors such as a manufacturer's track record, quality systems and supply consistency matter for continuity of treatment. These are clinical considerations discussed individually — not a public ranking of brands.

Because an approved generic contains the same molecule as the originator, the clinical effect is the same; the large difference in price is not explained by any clinical superiority of the more expensive product. What a patient needs is not the "best brand" from a list, but the right decision for their situation, made with a physician.

The Dangers of Self-Medicating With GLP-1 Medicines

Here is what can go wrong without medical oversight:

Wrong dose titration. Semaglutide must be started at a low dose and increased gradually over several weeks. Starting too high causes severe nausea, vomiting and dehydration — a frequent reason patients who self-start have to stop the medicine.

Missing underlying conditions. Before prescribing, a physician checks parameters such as HbA1c, fasting insulin, kidney and liver function, a thyroid panel (these medicines are contraindicated in people with a personal or family history of medullary thyroid cancer), and lipids. This is the standard of care at our diabetes treatment programme. Skipping these checks can be hazardous.

Muscle loss instead of fat loss. Without nutritional monitoring, patients on GLP-1 medicines can lose muscle along with fat — particularly risky in older people. Tracking body composition and protein intake, not just the number on the scale, is part of supervised care.

Counterfeit or substandard products. With many products in the market, counterfeit or poor-quality items are a real risk. Obtain medicines only from licensed pharmacies. If a price seems too good to be true, it probably is.

Who Might Be a Candidate — and Who Is Not

May be appropriate for: people with type-2 diabetes not adequately controlled on current treatment; people with a BMI above 30 (or above 27 with conditions such as diabetes, hypertension or sleep apnoea); people with PCOS-related metabolic syndrome; and those who have tried lifestyle change for several months without adequate results.

Not suitable for: pregnant or breastfeeding women; people with a personal or family history of medullary thyroid carcinoma or MEN2; active pancreatitis; severe kidney disease; and those with certain severe gastrointestinal conditions.

Requires careful, individual assessment: people on insulin (dose adjustment needed); people with retinopathy; elderly patients (higher risk of dehydration and muscle loss); and those with a history of gallbladder disease. This is exactly why these medicines need a physician — not a pharmacy counter.

What About Mounjaro (Tirzepatide)?

With generic semaglutide now far more affordable, patients ask whether they should consider semaglutide or tirzepatide. Tirzepatide (brand name Mounjaro) is a dual GIP/GLP-1 agonist that has shown greater average weight loss in clinical trials — I cover the comparison in my semaglutide vs tirzepatide guide. It remains considerably more expensive and has no Indian generic yet, as its patent is still in force. (Patients also ask about Zepbound — see is Zepbound available in India.)

As a general clinical approach, many patients are reasonably started on semaglutide, with tirzepatide considered if the response at the maximum tolerated dose is inadequate after a few months. Which is right for you is an individual decision — not a default — and is made in consultation.

Frequently Asked Questions